<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315990</url>
  </required_header>
  <id_info>
    <org_study_id>DERMATUX</org_study_id>
    <nct_id>NCT01315990</nct_id>
  </id_info>
  <brief_title>FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema</brief_title>
  <acronym>DERMATUX</acronym>
  <official_title>Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Carl Schimanski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this interventional study is to assess the progression free survival (one&#xD;
      year) of patients with treatment of FOLFIRI and cetuximab, combined with an optional dermal&#xD;
      prophylaxis.&#xD;
&#xD;
      Further Objectives:&#xD;
&#xD;
        1. Development of acneiforme follicular exanthema &gt;= grade 2&#xD;
&#xD;
        2. Duration until development of acneiforme follicular exanthema &gt;= grade 2&#xD;
&#xD;
        3. Development of paronychia&#xD;
&#xD;
        4. Development skin fissure (hand and foot)&#xD;
&#xD;
        5. Objective remission according RECIST 1.1&#xD;
&#xD;
        6. Rate of secondary resections of liver metastasis with a curative approach&#xD;
&#xD;
        7. Assessment of safety and tolerability&#xD;
&#xD;
        8. Overall survival&#xD;
&#xD;
        9. Progression free survival&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with metastatic colorectal cancer and confirmed KRAS-wildtype status in 1st line&#xD;
      therapy will be included in this phase IV-study. Subject will receive a regimen of FOLFIRI in&#xD;
      combination with Cetuximab every two weeks during study treatment phase. Treatment continues&#xD;
      until&#xD;
&#xD;
        -  disease progression&#xD;
&#xD;
        -  complete response&#xD;
&#xD;
        -  development of status of operability&#xD;
&#xD;
        -  an uncontrollable exanthema grade 3 or 4 or&#xD;
&#xD;
        -  intolerable toxicity is diagnosed. After study discontinuation or end of treatment,&#xD;
           respectively, patients will be followed up until the the last patient was treated for 12&#xD;
           months and has completed the 36-months follow up phase. Tumor response will be evaluated&#xD;
           (according to RECIST 1.1) every 12 weeks and at the end of study treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Progression-free survival rate at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to end of follow-up-phase (36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Objective response rate over the entire treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>The time from regsitration date to the date of death</time_frame>
    <description>Overall survival time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration until development of acneiforme follicular exanthema &gt;= grade 2</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Duration until development of acneiforme follicular exanthema &gt;= grade 2 during treatment-phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of paronychia</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Development of paronychia during treatment-phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of skin fissure (hand and foot)</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Development of skin fissure (hand and foot) during treatment-phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of secondary resections of metastasis of liver with a curative approach</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Rate of secondary resections of metastasis of liver with a curative approach during treatment-phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety and tolerability</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Assessment of safety and tolerability during treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of acneiforme follicular exanthema &gt;= grade2</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Development of acneiforme follicular exanthema &gt;= grade2 during treatment phase</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>FOLFIRI + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI + Cetuximab</intervention_name>
    <description>Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).&#xD;
FOLFIRI regimen&#xD;
Administration Schedule:&#xD;
Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)&#xD;
Irinotecan 180 mg/m² iv , 90 min on day 1&#xD;
Folic acid (racemic) 400 mg/m², 120 min on day 1&#xD;
5-FU 400 mg/m² bolus on day 1&#xD;
5-FU 2400 mg/m² iv over 46 h on day 1 to 2</description>
    <arm_group_label>FOLFIRI + Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed metastatic colorectal cancer (primary tumor or metastasis)&#xD;
&#xD;
          -  Confirmation of KRAS wildtype status&#xD;
&#xD;
          -  Confirmation of EGFR-Expression in the tumor&#xD;
&#xD;
          -  Stadium IV&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Qualified for an application of FOLFIRI + Cetuximab treatment&#xD;
&#xD;
          -  Signed patient informed consent form&#xD;
&#xD;
          -  Of either gender and aged 18 years or more&#xD;
&#xD;
          -  Estimated lifespan more than 3 months&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 guidelines. The evaluation has to be max. 4&#xD;
             weeks&#xD;
&#xD;
          -  Effective and adequate contraceptive precautions of man or woman in a childbearing&#xD;
             potential age (double barrier method)&#xD;
&#xD;
          -  Leucocytes ≥ 3,0 x 10^9/L with neutrophils ≥ 1,5 x 10^9/L, thrombocytes ≥ 100 x&#xD;
             10^9/L, haemoglobin ≥ 5,6 mmol/L&#xD;
&#xD;
          -  Serum bilirubin ≤ 1,5 x ULN (upper limit of normal)&#xD;
&#xD;
          -  ALAT and ASAT ≤ 2,5 x ULN; if metastasis in liver, than ALAT and ASAT ≤ 5 x ULN&#xD;
&#xD;
          -  Serum creatinin ≤ 1,5 x ULN&#xD;
&#xD;
          -  If applicable a prior operation has to be min. 4 weeks ago, biopsy more than 1 week&#xD;
             until initiation of treatment. Wounds of operations had to be completely cured&#xD;
&#xD;
          -  No toxicity of prior treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  KRAS-gene mutation&#xD;
&#xD;
          -  Confirmation of non-EGFR-Expression&#xD;
&#xD;
          -  Prior treatment with an EGRF-receptor inhibitor&#xD;
&#xD;
          -  Prior chemotherapy of the mCRC, except (neo-)adjuvant therapy, which had to be ended&#xD;
             min. 6 months before recruitment&#xD;
&#xD;
          -  Experimental treatment medication within 30 days before recruitment&#xD;
&#xD;
          -  Known hypersensitivity against components of the chemotherapy, cetuximab, doxycycline,&#xD;
             Reconval K1 or Dermatop&#xD;
&#xD;
          -  Rosacea&#xD;
&#xD;
          -  Other chronic dermal diseases with development of papula or pustule&#xD;
&#xD;
          -  Known lung fibrosis or interstitial pneumonitis or interstitial lung diseases&#xD;
&#xD;
          -  keratitis, ulcerative keratitis or severe form of dry eye&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Brain metastasis&#xD;
&#xD;
          -  Clinical relevant coronary heart disease, myocardial infarction within the last 12&#xD;
             months or high risk of uncontrollable arrhythmia&#xD;
&#xD;
          -  Acute or subacute ileus or chronic colon-inflammation or chronic diarrhea&#xD;
&#xD;
          -  Symptomatic peritoneal carcinomatosis&#xD;
&#xD;
          -  Serious, non-healing wounds, ulcera or bone fractures&#xD;
&#xD;
          -  Uncontrollable arterial hypertension&#xD;
&#xD;
          -  Therapeutic anticoagulation (e.g. therapy with marcumar)&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  Gilbert-Meulengracht-syndrome&#xD;
&#xD;
          -  Other malignant tumours less than five years old. Exceptions include basocellular&#xD;
             carcinoma or an in situ cancer of the cervix uteri if they are curative treated as&#xD;
             well as an untreated, locally confined, asymptotic &quot;low risk&quot; (indolent) prostata&#xD;
             carcinoma (Stage T ≤ T1-2a, PSA &lt; 15 ng/ml, Gleason-Score ≤ 6 ).&#xD;
&#xD;
          -  Known abuse of narcotic drugs or alcohol&#xD;
&#xD;
          -  Any kind of disorder that compromises the ability of the subject to give written&#xD;
             informed consent and/or comply with the study procedures&#xD;
&#xD;
          -  Any significant concomitant disease that excludes the participation to the study&#xD;
&#xD;
          -  Missing or limited juristic contractual capability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Christoph Schimanski, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Dr. Carl Schimanski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Phase IV Study</keyword>
  <keyword>Metastatic Colorectal Cancer (mCRC</keyword>
  <keyword>Cetuximab (Erbitux)</keyword>
  <keyword>first-line treatment</keyword>
  <keyword>acneiform follicular exanthema</keyword>
  <keyword>rash</keyword>
  <keyword>vitamin K1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Exanthema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

